Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
life sciences
3
×
boston blog main
boston top stories
national blog main
agios pharmaceuticals
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
biologic drugs
boehringer ingelheim
boston
boston xcon
boulder/denver xcon
cancer
cancer drugs
david e. shaw
deals
detroit xcon
dicerna pharmaceuticals
digital health
drug development
drug discovery
eli lilly
enasidenib
fda
genome sequencing
healthtech
hepatitis b
indiana blog main
indiana top stories
indiana xcon
innovation
investing
ipo
ivosidenib
johnson & johnson
materials science
morphic
What
development
3
×
medicines
3
×
today
abandoning
ago
baggage
biologic
bottleneck
clinical
companies
company’s
course
cuts
deal
dicerna
discover
dramatically
drug
experimental
fixing
free
genomic
gets
growing
handiwork
helped
interference
internal
ipo
landscape
long
making
medicine
past
patients
pharma
pipeline
priority
rna
rnai
Language
unset
Current search:
medicines
×
development
×
biotech
×
" life sciences "
×
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority
